Indoor Biotechnologies, a global immunodiagnostics and biotechnology company based in Cardiff in the UK, was recently awarded funding from Innovate UK to develop a COVID-19 test using T cells. Successfully identifying individuals that have already been infected and have immunity would allow society to safely return to normal. In addition, reliable testing methods are needed since the symptoms of COVID-19 vary from person to person, with some not even displaying symptoms.
A potential method for a COVID-19 test is done by searching for specific antibodies in the blood samples. Several antibody tests are available, but doubts are present regarding the reliability of knowing if a person has gained immunity.
Long-term protection from viruses doesn’t only come from antibodies, but also from other cells of the immune system such as T cells, that play a vital role in eradicating and controlling viral infections. The latest test proposed by Indoor Biotechnologies focuses on the T cells rather than antibodies. If it is successful, the COVID-19 test or Simple Cellular Immunity Test (SCIT) will be able to identify the presence of T cells that cause COVID-19 from a single tube of blood and within 24 hours.
This method has the ability to be more sensitive and more reliable at determining immunity than antibody testing. In order to validate this, it will be tested on individuals that already carried the virus and have developed antibodies. The COVID-19 test is also very valuable during vaccine development in order to help identify whether an adequate immune response has been created to protect people against coronavirus, and for testing how long the immune response lasts.